Académique Documents
Professionnel Documents
Culture Documents
ABOUT AXIOMX
AxioMx is applying knowledge gained from the past 15 years of human genome sequencing to produce highly specific recombinant antibodies against the human proteome. The existing antibody development paradigm is too slow and does not always result in consistent, renewable, and quality antibodies. Through proprietary advances in traditional phage display antibody library design, phage display screening and affinity maturation technologies, we rapidly generate antibodies at the required binding and specificity criteria. At AxioMx, we believe our platform will lead to the wide adoption of recombinant antibody use in research and diagnostic applications.
Technology Summary
AxioMx has developed synthetic recombinant antibody libraries, commonly known as phage display libraries, with greater than ten billion unique clones. Diversity in our libraries is restricted to the most variable positions in the complementarity determining regions (CDRs) of natural antibody sequences. Our antibody frameworks have been optimized for protein expression, and our libraries efficiently generate binders to peptides as well as protein antigens. We utilize a "rapid liquid approach" in our automated phage display screening methodology to select for antibodies with both high affinity and high specificity.
CONTACT US
AxioMx, Inc. 688 East Main Street Branford, CT 06405 Main: 203-208-1918 Fax: 203-433-4068 Directions: Take I-95 to exit 55 for US-1 / East Main Street toward North Branford Turn right onto US-1 / East Main Street Travel 1.7 miles on US-1 / East Main Street to 688 E. Main Street